Eli Lilly and Company (LLY)vsMednax Inc (MD)
LLY
Eli Lilly and Company
$1,102.08
+0.45%
HEALTHCARE · Cap: $1.01T
MD
Mednax Inc
$23.87
+1.07%
HEALTHCARE · Cap: $2.00B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 3640% more annual revenue ($72.25B vs $1.93B). LLY leads profitability with a 35.0% profit margin vs 9.0%. MD appears more attractively valued with a PEG of 0.24. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
MD
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+65.0%
Fair Value
$61.27
Current Price
$23.87
$37.40 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Growing faster than its price suggests
Attractively priced relative to earnings
Earnings expanding 50.0% YoY
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 31.6x book value
3.9% revenue growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : MD
The strongest argument for MD centers on PEG Ratio, P/E Ratio, EPS Growth. PEG of 0.24 suggests the stock is reasonably priced for its growth.
Bear Case : LLY
The primary concerns for LLY are PEG Ratio, Debt/Equity, P/E Ratio. A P/E of 40.2x leaves little room for execution misses.
Bear Case : MD
The primary concerns for MD are Revenue Growth, Altman Z-Score, Market Cap.
Key Dynamics to Monitor
LLY profiles as a growth stock while MD is a value play — different risk/reward profiles.
MD carries more volatility with a beta of 0.70 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 66/100), backed by strong 35.0% margins and 55.5% revenue growth. MD offers better value entry with a 65.0% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Mednax Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
MEDNAX, Inc., provides neonatal, maternal-fetal, pediatric cardiology, and other pediatric subspecialties in the United States and Puerto Rico. The company is headquartered in Sunrise, Florida.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?